News

Hosted on MSN25d
Biogen’s higher dose Spinraza under review by US and EU regulators
The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted Biogen’s applications for a higher dose regimen of spinal muscular atrophy (SMA) treatment Spinraza ...
pharmaphorum3d
Biogen/Ionis could launch rare disease drug within weeks
Biogen and Ionis Pharmaceuticals’ Spinraza could be on the US market within weeks after a phase 3 trial in the rare neuromuscular disorder, spinal muscular atrophy, met its goal. The ...
Hosted on MSN1mon
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure ...
SMA News Today5d
In SMA, Spinraza boosts signals in nerves that supply muscles
Motor improvements in SMA adults treated with Spinraza paralleled a boost in electrical impulses along nerves that supply ...
CNN23d
Biogen Inc.
Biogen, Inc. is a biopharmaceutical company ... TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM ...
ADVFN1mon
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
Biogen licensed the global rights to develop, manufacture and commercialize SPINRAZA from Ionis Pharmaceuticals, Inc. (Nasdaq: IONS). Please click here for Important Safety Information and ...